147 related articles for article (PubMed ID: 26282411)
1. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
Micheli V; Regazzi M; Dickinson L; Meraviglia P; Villani P; Khoo SH; Viganò P; Cordier L; Cusato M; Duca P; Orlando G; Rizzardini G; Back DJ; Cargnel A
Ther Drug Monit; 2008 Jun; 30(3):306-13. PubMed ID: 18520602
[TBL] [Abstract][Full Text] [Related]
4. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
[TBL] [Abstract][Full Text] [Related]
5. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
[TBL] [Abstract][Full Text] [Related]
7. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
8. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
11. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
Abdalla S; Compagnucci A; Riault Y; Chan MK; Bamford A; Nolan A; Ramos JT; Constant V; Nguyen T-N; Zheng Y; Tréluyer J-M; Froelicher-Bournaud L; Neveux N; Saidi Y; Cressey TR; Hirt D;
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0100423. PubMed ID: 38092664
[TBL] [Abstract][Full Text] [Related]
13. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
Lapadula G; Costarelli S; Chatenoud L; Castelli F; Astuti N; Di Giambenedetto S; Quiros-Roldan E; Sighinolfi L; Ladisa N; Di Pietro M; Zoncada A; Di Filippo E; Gori A; Nasta P; Torti C;
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):312-8. PubMed ID: 25723139
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B; Moreno A; Pérez-Elías MJ; Quereda C; Dronda F; Casado JL; Madrid-Elena N; Aguilar M; Fumero E; Moltó J; Moreno S
J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
[TBL] [Abstract][Full Text] [Related]
15. Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.
Morsica G; Bianchi G; Bagaglio S; Conte C; Salpietro S; Porrino L; Uberti-Foppa C
New Microbiol; 2011 Jul; 34(3):317-21. PubMed ID: 21811753
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.
Abdalla S; Compagnucci A; Zheng Y; Tréluyer JM; Saidi Y; Ramos JT; Coelho A; Riault Y; Cressey TR; Hirt D;
J Antimicrob Chemother; 2023 Apr; 78(4):1041-1049. PubMed ID: 36869720
[TBL] [Abstract][Full Text] [Related]
17. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Bartels H; Decosterd L; Battegay M; Marzolini C
J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
[TBL] [Abstract][Full Text] [Related]
18. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
19. HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests.
Domínguez Domínguez L; Matarranz M; Lagarde M; Bisbal O; Hernando A; Lumbreras C; Rubio R; Pulido F
Rev Esp Enferm Dig; 2019 Aug; 111(8):626-632. PubMed ID: 31240941
[TBL] [Abstract][Full Text] [Related]
20. Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Clotet B
Antimicrob Agents Chemother; 2012 Jun; 56(6):2837-41. PubMed ID: 22430963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
